Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dostarlimab plus CAPEOX vs CAPEOX in MMRp/MSS colon cancer
2024-513441-36-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of dostarlimab in colon cancer (2 arms), sponsored by GSK. Primary endpoints: Major pathological response rate and Safety and tolerability. Planned start Nov 2024; status: authorised.
02
Drugs
dostarlimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2024-513441-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513441-36-00.